secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001104659-24-032379
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma raises $6.5M via public offering; FDA clears teen enrollment in Netherton Syndrome trials
--------------------------------------------------------------------------------

- Raised $6.5M gross from public offering of ADSs, pre-funded and Series D/E warrants at $1.60 combined per unit.
- Repriced 638,834 existing warrants from $13.20/$12.00 to $1.60 per ADS; extended expiration to March 7, 2029.
- FDA cleared recruitment of teen subjects (14+) into QRX003 trials for Netherton Syndrome, first non-adult inclusion under open IND.
- Teens on off-label systemic therapy eligible for open-label study; others eligible for placebo-controlled study.
- Net proceeds for general corporate purposes; offering closed March 7, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/0001104659-24-032379-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/tm248307d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-032379

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer